Theravance Biopharma, Inc. (TBPH)

9.52 -0.17 (-1.75%) At close: 04:00PM EDT

Theravance Biopharma, Inc.

901 Gateway Boulevard
South San Francisco, CA 94080
United States
650 808 6000
https://www.theravance.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 99

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Rick E. Winningham M.B.A.	Chairman & CEO	1.3M	N/A	1960
Mr. Aziz Sawaf C.F.A.	Senior VP & CFO	583.5k	N/A	1982
Stuart Knight	VP of IT&I & Chief Information Officer	N/A	N/A	N/A
Ms. Gail B. Cohen	Vice President of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Brett A. Grimaud Esq.	Senior VP, General Counsel & Secretary	N/A	N/A	1974
Ms. Rhonda F. Farnum	Chief Business Officer and Senior VP of Commercial & Medical Affairs	942.81k	N/A	1965
Ms. Stacy L. Pryce	Senior VP & Chief Strategy Officer	N/A	N/A	N/A
Dr. Aine Miller Ph.D.	SVP of Dev., VP of Regu., Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Corporate governance

Theravance Biopharma, Inc.’s ISS governance QualityScore as of 1 April 2024 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.